Graduate School of Medicine and Faculty of Medicine, Kyoto University

SK-II UNVEILS SKIN AGING DISCOVERIES AT THE WORLD CONGRESS OF DERMATOLOGY 2023 AND INAUGURATES THE PITERA™ SCIENCE EXPERT PANEL

Retrieved on: 
Wednesday, July 19, 2023
Trigger, Cream, SK-II, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Beth Israel Deaconess Medical Center, AT-02, Weill Cornell Graduate School of Medical Sciences, Medicine, DEPT, Physician, Postgraduate education, Ageing, Kyushu University, Research, Associate, Science, Harvard Medical School, Congress, Professor, Kyoto University, MPH, Human, Skin, Cosmetics, Pharmaceutical industry, Management, Dermatology, MD

SINGAPORE, July 19, 2023 /PRNewswire/ -- Pushing the boundaries of skin aging science and innovations, global prestige skincare brand SK-II debuts new skin aging discoveries and innovations and inaugurates its first PITERA™ Science Expert Panel with some of the world's leading dermatologists. 

Key Points: 
  • SINGAPORE, July 19, 2023 /PRNewswire/ -- Pushing the boundaries of skin aging science and innovations, global prestige skincare brand SK-II debuts new skin aging discoveries and innovations and inaugurates its first PITERA™ Science Expert Panel with some of the world's leading dermatologists.
  • A pioneering longitudinal 10-year Akita Study and the PITERA™ 24/7 Skin Fluctuation Study on young skin has contributed to PITERA™ breakthroughs on skin.
  • If left untreated, the aging chain reaction can lead to accelerated aging signs, resulting in more severe signs of premature aging.
  • Following the World Congress of Dermatology, SK-II inaugurates its first-ever PITERA™ Science Expert Panel in recognition of some of the world's foremost dermatologists who have partnered with SK-II to advance skin aging science.

Fujitsu, Kyoto University, and Chordia Therapeutics launch AI trials to discover biomarkers for new cancer drugs

Retrieved on: 
Wednesday, May 17, 2023
Probability, Drug development, Cancer, Biomarker, RNA, Patient, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto University, Fujitsu, Diagnosis, Therapy, Gene, Genome, Pharmaceutical industry, Chordia

This information will assist researchers working to discover biomarkers for patient stratification that can be used to determine the efficacy of cancer treatments that target RNA regulatory stress (5), under development by Kyoto University and Chordia since May 2018.

Key Points: 
  • This information will assist researchers working to discover biomarkers for patient stratification that can be used to determine the efficacy of cancer treatments that target RNA regulatory stress (5), under development by Kyoto University and Chordia since May 2018.
  • Through this demonstration, Fujitsu, Kyoto University, and Chordia Therapeutics aim to realize new cancer treatments personalized to individual patients' genetic characteristics, cancer symptoms and progression, ultimately improving patient outcomes and well-being.
  • A variety of biomarkers are currently used in the medical field for preventative care, diagnosis, and treatment selection of cancer.
  • In clinical trials, biomarkers make it possible for drug development researchers to focus on specific characteristics, improving the likelihood of developing successful and effective new drug candidates.